Office of Management and Budget
Executive Office of the President
  Site Search     
About OMB  
- Organization Chart
- Contact OMB
President's Budget
- Budget Documents
- Supplementals, Budget Amendments, and Releases
Federal Management
- President's Management Agenda
- Office of Federal Financial
-- Agency Audits
- Office of Federal Procurement
  -- CAS Board
-- FAIR Act Inventory
Office of Information and Regulatory Affairs
- OIRA Administrator
- Regulatory Matters
- Paperwork Requirements
- Statistical Programs & Standards
- Information Policy, IT & E-Gov
Communications & Media
- News Releases
- Speeches
Legislative Information
- Statements of Administration Policy (SAPs)
- Testimony
- Reports to Congress
Information for Agencies
- Circulars
- Memoranda
- Bulletins
- Pivacy Guidance
- Grants Management
- Reports
Site Map
First Gov  

July 29, 1998

H.R. 872 - Biomaterials Access Assurance Act of 1998
(Gekas (R) Pennsylvania and 135 cosponsors)

The Administration supports House passage of the manager's amendment to H.R. 872 which would protect certain biomaterials suppliers from liability for harm caused by a medical implant for which they provided raw materials or component parts. In vetoing legislation that included a separate biomaterials title in 1996, the President expressed general support for the goals of the biomaterials bill, but objected to the language because it would have protected from liability even those suppliers who knew or should have known that the materials, as implanted, would cause injury. The bill before the House does not protect those suppliers whose negligence or intentionally tortious conduct was a cause of the harm if: (1) the manufacturer's liability should be reduced because of that negligence or intentionally tortious conduct; or (2) the manufacturer is insolvent. This bill is narrowly crafted to address the demonstrated problem that the supply of life-saving and life-enhancing bodily implants is threatened by the refusal of suppliers of raw materials and component parts to provide their materials and parts because their potential costs of defending against liability claims exceed their profits from sale of the materials and parts.